低剂量IL-2治疗伴免疫紊乱的骨髓增生异常综合征三例报告
本文报告3例伴系统性炎症或自身免疫表现的骨髓增生异常综合征(MDS)患者,均依赖激素且对生物制剂或阿扎胞苷无效,接受低剂量IL-2(ld-IL2)治疗。结果显示2/3患者临床改善并减少激素用量,无严重不良事件及疾病进展。作者认为值得在对照研究中进一步验证ld-IL2在此类患者中的作用。
要点
- 3例MDS伴免疫紊乱患者中2例经ld-IL2获临床改善并减少激素用量
- 治疗期间无严重不良事件,未见疾病进展
核心结论
- 低剂量IL-2在3例MDS伴免疫紊乱患者中使2/3获得临床改善和激素减量,无严重不良事件及疾病进展。
研究设计与样本
- 三例病例报告;3例MDS伴相关免疫紊乱患者(风湿性多肌痛、复发性多软骨炎伴Sweet综合征、伴皮肤和关节受累的血管炎)均依赖激素且对生物制剂或阿扎胞苷无效。
主要发现
- 治疗使2/3患者临床改善并减少激素用量,无严重不良事件,无疾病进展。
临床怎么用
- 结果提示ld-IL2可能作为MDS伴免疫紊乱患者减少激素用量的探索性选择,需在对照临床研究中进一步验证。
局限性
- 仅为3例病例报告,样本量小,无对照组,结论需对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic inflammatory and autoimmune diseases can be associated with myelodysplastic syndromes. Current treatments (steroids, immunosuppressive agents, biologics) are unsatisfactory because of their low response rate, dependence or adverse events. We aimed at evaluating the effects of low doses of IL-2 (ld-IL2) as a regulatory T-cell inducer in this context. METHODS: We treated three patients with ld-IL2 with myelodysplastic syndromes and an associated dysimmune disorder (polymyalgia rheumatic, relapsing polychondritis associated with Sweet's syndrome and vasculitis with cutaneous and joint involvement, respectively). All three patients were dependent on steroids and refractory to biologics or azacitidine. They received doses of 1-1.5 million units of proleukin/day during 5 days and then every fortnight. RESULTS: The treatment led to a clinical improvement and steroid sparing in 2/3 patients with no serious adverse events, and no progression of the disease. CONCLUSION: Our results support the investigation of ld-IL2 in MDS associated with immune disorders in controlled clinical studies.
引用
- Corfmat M, Willekens C, Vinit J, et al. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report. Rheumatology (Oxford). 2021. PMID: 33164099. doi:10.1093/rheumatology/keaa696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。